– Pivotal AUGMENT-101 trial met its primary endpoint at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); CR/CRh rate consistent across adult and pediatric patients – – 63% ...
– Trial met its primary endpoint with a CR/CRh rate of 23% at interim analysis of the pooled KMT2Ar AML and ALL cohorts (p-value = 0.0036); an additional 14% of patients proceeded to transplant ...
WALTHAM, Mass., April 8, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the ...
- 30% CR/CRh rate in efficacy evaluable population; 27% CR/CRh rate observed in both mNPM1 and KMT2Ar (MLLr) R/R acute leukemia patients treated at RP2D - - 9 of 12 patients who underwent stem cell ...
WALTHAM, Mass., March 15, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced that data from the Phase 1 portion of the ongoing Phase 1/2 AUGMENT-101 trial of revumenib in ...
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia From October 1, 2021, to ...
– Favorable safety and tolerability profile; treatment discontinuations were low at 6% with none due to differentiation syndrome or QTc prolongation – – Supportive results from the AUGMENT-101 trial, ...
AUGMENT-101 is a Phase 1/2 open-label trial designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of orally administered revumenib. The Company previously announced positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results